First Generic Naloxone Nasal Spray Gets FDA Approval
The FDA has granted final approval for the first generic version of Narcan (naloxone hydrochloride nasal spray; Adapt Pharma) to Teva Pharmaceuticals.
All articles by Steve Duffy
Kidney Disorder Risk Examined Among Various Bipolar Disorder Drug Regimens
According to the results of a retrospective observational study, the majority of pharmacotherapies used for the treatment of bipolar disorder (BD) are associated with some risk of kidney disorder (KD).
Not so Inactive: Excipients in Medications May Trigger Adverse Reactions in Some Patients
A team of investigators from both Brigham and Women’s Hospital and the Massachusetts Institute of Technology analyzed data on thousands of inactive ingredients in approved medications to further characterize them and enhance our knowledge of their safety.
FDA: Seizures Reported Following E-Cigarette Use
The Food and Drug Administration (FDA) is notifying the public that cases of seizures have been reported following the use of e-cigarettes.
Can Maternal Diet Affect the Risk of ADHD Development in Offspring?
A higher omega-6 to omega-3 ratio in the mother’s diet may increase the risk of attention deficit hyperactivity disorder (ADHD) symptoms in offspring, according to findings from a study published in the Journal of Pediatrics. Researchers quantified the levels of omega-6 and -3 that reached the fetus by sampling umbilical cord plasma. Omega-3 and omega-6…
FDA Clears Unique Medical Device for Anxiety, Depression, Insomnia Treatment
The Food and Drug Administration (FDA) has approved a new cranial electrotherapy stimulator (CES) device for the treatment of anxiety, depression, and insomnia.
Stimulation Device for MDD Cleared for Much Shorter Treatment Session
The Food and Drug Administration (FDA) has cleared a 3-minute session protocol, Theta Burst Stimulation, for the NBT System (Nexstim) used to treat major depressive disorder (MDD). Previously, the standard protocol time for the therapy was 37 minutes.
FDA Warns Company Selling Misbranded Drugs With False Claims
The Food and Drug Administration (FDA) issued a warning letter to NutraPharma, for selling false and misleading products that claim to treat addiction and chronic pain. The products are sold via the website nyloxin.com.
Next post in Addiction
